State Research Center of Virology and Biotechnology: COVID-19 Vaccine Patented


Государственный научный центр вирусологии и биотехнологии «Вектор»


Experts from the Federal Institute of Industrial Property (FIPS) have completed the second examination phase related to the medicines from coronavirus infection SARS-Cov-2.

The State Scientific Center of Virology and Biotechnology "Vector", located in Novosibirsk, has received patents for the vaccine from COVID-19. Before that, the Gamaleya Research Institute of Epidemiology and Microbiology obtained patents for its two-component coronavirus vaccine.

Unlike their colleagues, Novosibirsk researchers developed the vaccine that contains fragments extracted from the virus — synthetic peptide antigens. The antigens-based vaccine provokes an immune reaction against COVID-19 and promotes the further development of immunity. A total of three patents have been issued for inventions, each of which contains a specific modified virus fragment. The authors of the invention are Ilnaz Imatdinov, Maria Bochkareva, Elena Prudnikova, Anton Tishin, Oleg Pyakov, Elena Gavrilova, and Rinat Makshutov.

The FIPS experts who dealt with the patent applications, after conducting an information search and examination, confirmed the vaccine patentability and worldwide novelty degree. Vaccines developed by the leading Russian research institutions will make it possible to vaccinate the Russian population to the fullest extent possible and thus prevent the further spread of coronavirus infection.

"Since the pandemic began, Russian inventors have submitted around 300 applications for inventions aimed at combating COVID-19. To date, more than 55 patents have been granted. About two dozen applications were rejected because they did not have worldwide novelty or did not correspond to the existing documents requirements. The remaining applications are being processed. Applications for inventions to combat COVID-19 are given priority consideration for an average of 22 days", noted Rospatent’s Head Grigory Ivliev.

On July 24, the State Scientific Center of Virology and Biotechnology "Vector" received the permission of the Russian Ministry of Health to carry out vaccine clinical trials on volunteers. Earlier, Head of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) Anna Popova stated that the clinical trials would end on September 30, then the post-registration phase would begin.




Last page update:

All updates
next news
Russia and China discussed bilateral cooperation in the IP field
go to news list

Font size